Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Oct;18(5):430-432.
doi: 10.7861/clinmedicine.18-5-430.

Lesson of the month 1: Sodium valproate-induced encephalopathy

Affiliations
Review

Lesson of the month 1: Sodium valproate-induced encephalopathy

Lara Camilleri. Clin Med (Lond). 2018 Oct.

Abstract

A 69-year-old man developed reduced consciousness of sudden onset. Examination and parameters were normal, except for a Glasgow Coma Scale (GCS) score of six. Brain imaging and blood tests were also normal, except for high plasma ammonia. His past medical history included epilepsy, hypertension and colitis. He was taking multiple antiepileptic medications, including sodium valproate, with no recent dose alterations. Medical intervention led to the sodium valproate being stopped and naloxone being administered. The patient's level of responsiveness and ammonia levels gradually improved. The patient was also being treated with ciprofloxacin for a urinary tract infection and a newly developed syndrome of inappropriate antidiuretic hormone secretion treated with demeclocycline. There is an association between long-term sodium valproate use and low carnitine levels, especially in the setting of polypharmacy. This in turn precipitates hyperammonaemia and encephalopathy. This case highlights the importance of an adequate drug history and the awareness of serious but uncommon adverse effects.

Keywords: Sodium valproate; encephalopathy; hyperammonaemia; naloxone.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Ghodke-Puranik Y. Thorn CF. Lamba JK, et al. Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2013;23:236–41. - PMC - PubMed
    1. Vazquez M. Fagiolino P. Maldonado C, et al. Hyperammonaemia associated with valproic acid concentrations. Biomed Res Int. 2014;2014:217269. - PMC - PubMed
    1. Mittal V. Muralee S. Tampi RR. Valproic acid induced hyperammonaemia in the elderly: a review of the literature. Case Rep Med. 2009;2009:802121. - PMC - PubMed
    1. Lheureux PE. Penaloza A. Zahir S. Gris M. Science review: Carnitine in the treatment of valproic acid induced toxicity - what is the evidence? Crit Care. 2005;9:431–40. - PMC - PubMed
    1. Carr RB. Shrewsberry K. Hyperammonaemia due to valproic acid in the psychiatric setting. Am J Psychiatry. 2007;164:1020–7. - PubMed

MeSH terms